{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:22:00Z","timestamp":1782310920050,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000040","name":"Agriculture and Agri-Food Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000040","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manitobas Agri-Food Research and Development Initiative (ARDI)","award":["12-1127"],"award-info":[{"award-number":["12-1127"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vph.2016.06.007","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T08:50:48Z","timestamp":1467449448000},"page":"60-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial"],"prefix":"10.1016","volume":"87","author":[{"given":"Shuaihua","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Rodr\u00edguez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanu Ramkumar","family":"Ramprasath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Segura-Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2016.06.007_bb0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","article-title":"Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein b lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms","volume":"130","author":"Rashid","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.06.007_bb0010","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1194\/jlr.E800008-JLR200","article-title":"PCSK9 function and physiology","volume":"49","author":"Peterson","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2016.06.007_bb0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cca.2014.10.044","article-title":"PCSK9 and its modulation","volume":"440","author":"Cui","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.vph.2016.06.007_bb0020","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.vph.2016.06.007_bb0025","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.vph.2016.06.007_bb0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2016.06.007_bb0035","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.numecd.2015.01.006","article-title":"Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease","volume":"25","author":"Zhang","year":"2015","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.vph.2016.06.007_bb0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.vph.2016.06.007_bb0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of african descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.vph.2016.06.007_bb0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/clc.22014","article-title":"Design and rationale of the laplace-timi 57 trial: a phase ii, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy","volume":"35","author":"Kohli","year":"2012","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.vph.2016.06.007_bb0055","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2016.06.007_bb0060","author":"FDA US"},{"key":"10.1016\/j.vph.2016.06.007_bb0065","author":"FDA US"},{"key":"10.1016\/j.vph.2016.06.007_bb0070","doi-asserted-by":"crossref","DOI":"10.3402\/fnr.v58.25145","article-title":"Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review","volume":"58","author":"Schwab","year":"2014","journal-title":"Food Nutr. Res."},{"key":"10.1016\/j.vph.2016.06.007_bb0075","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1161\/01.CIR.100.11.1253","article-title":"Aha science advisory. Monounsaturated fatty acids and risk of cardiovascular disease. American heart association nutrition committee","volume":"100","author":"Kris-Etherton","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.06.007_bb0080","doi-asserted-by":"crossref","first-page":"e1000252","DOI":"10.1371\/journal.pmed.1000252","article-title":"Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Mozaffarian","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.vph.2016.06.007_bb0085","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1017\/S0007114511003436","article-title":"Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome","volume":"107","author":"Richard","year":"2012","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.vph.2016.06.007_bb0090","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3945\/ajcn.111.030114","article-title":"Effects of n\u22126 pufas compared with sfas on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial","volume":"95","author":"Bjermo","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.vph.2016.06.007_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1743-7075-10-4","article-title":"Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets","volume":"10","author":"Cariou","year":"2013","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.vph.2016.06.007_bb0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3945\/ajcn.113.081133","article-title":"Dha-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial","volume":"100","author":"Jones","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.vph.2016.06.007_bb0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vph.2015.07.001","article-title":"Marine n\u22123 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: a randomised study","volume":"76","author":"Graversen","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2016.06.007_bb0110","article-title":"Docosahexaenoic acid attenuates cardiovascular risk factors via a decline in proprotein convertase subtilisin\/kexin type 9 (PCSK9) plasma levels","author":"Rodriguez-Perez","year":"2015","journal-title":"Lipids"},{"key":"10.1016\/j.vph.2016.06.007_bb0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1745-6215-15-136","article-title":"Plasma fatty acid changes following consumption of dietary oils containing n\u22123, n\u22126, and n\u22129 fatty acids at different proportions: preliminary findings of the canola oil multicenter intervention trial (comit)","volume":"15","author":"Senanayake","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.vph.2016.06.007_bb0120","doi-asserted-by":"crossref","DOI":"10.3945\/ajcn.113.081133","article-title":"Dha-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial","author":"Jones","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.vph.2016.06.007_bb0125","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","article-title":"Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy","volume":"2","author":"Raal","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2016.06.007_bb0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"Werner","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2016.06.007_bb0135","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11745-009-3324-4","article-title":"Docosahexaenoic acid activates some srebp-2 targets independent of cholesterol and er stress in sw620 colon cancer cells","volume":"44","author":"Storvold","year":"2009","journal-title":"Lipids"},{"key":"10.1016\/j.vph.2016.06.007_bb0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0021-9150(01)00762-6","article-title":"Sterol-regulatory element-binding protein (srebp)-2 contributes to polygenic hypercholesterolaemia","volume":"164","author":"Miserez","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2016.06.007_bb0145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7150\/ijbs.3524","article-title":"An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte srebp-regulated genes","volume":"8","author":"Zhang","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.vph.2016.06.007_bb0150","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1194\/jlr.M000620","article-title":"Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels","volume":"51","author":"Troutt","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2016.06.007_bb0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tcm.2008.01.001","article-title":"Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms","volume":"18","author":"Paumelle","year":"2008","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.vph.2016.06.007_bb0160","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.06.007_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trsl.2012.01.010","article-title":"Serum levels of proprotein convertase subtilisin\/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin\/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways","volume":"160","author":"Cameron","year":"2012","journal-title":"Transl. Res."},{"key":"10.1016\/j.vph.2016.06.007_bb0170","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1194\/jlr.P023994","article-title":"Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia","volume":"53","author":"Huijgen","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.vph.2016.06.007_bb0175","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: reciprocal interaction with ldlr and additional lipid effects","volume":"238","author":"Tavori","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2016.06.007_bb0180","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ijcard.2014.04.224","article-title":"Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis","volume":"174","author":"Li","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2016.06.007_bb0185","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2013.01.005","article-title":"Association of serum proprotein convertase subtilisin\/kexin type 9 with carotid intima media thickness in hypertensive subjects","volume":"62","author":"Lee","year":"2013","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.vph.2016.06.007_bb0190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2014.07.010","article-title":"PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program","volume":"236","author":"Arsenault","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2016.06.007_bb0195","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2015.01.012","article-title":"PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension","volume":"239","author":"Berger","year":"2015","journal-title":"Atherosclerosis"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189116300027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189116300027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T15:58:38Z","timestamp":1568131118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189116300027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":39,"alternative-id":["S1537189116300027"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2016.06.007","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2016.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2016.10.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}